Применение высоких доз N-ацетилцистеина у пациентов со стабильным течением хронической обструктивной болезни легких Двойное слепое рандомизированное плацебо-контролируемое исследование HIACE Hoi Nam Tse, MBChB, FCCP; Luca Raiteri, MD; King Ying Wong, MB

1. Evans MD, Pryor WA. Cigarette smoking, emphysema, and damage to alpha 1-proteinase inhibitor. Am J Physiol 1994; 266 (6 pt 1): L593–L611.
2. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16 (3): 534–54.
3. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-infl ammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther 2007; 20 (1): 9–22.
4. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6 (6): 593–97.
5. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997; 38: 205–27.
6. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986; 50 (Suppl. 1): 31–42.
7. Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; (2): CD001287.
8. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22 (2): 209–21.
9. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365 (9470): 1552–60.
10. Antonelli-Incalzi R, Imperiale C, Bellia V et al. SaRA Investigators. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003; 22 (3): 444–9.
11. McFadden ER Jr, Linden DA. A reduction in maximum midexpiratory flow rate. A spirographic manifestation of small airway disease. Am J Med 1972; 52 (6): 725–37.
12. Gelb AF, Zamel N. Simplified diagnosis of small-airway obstruction. N Engl J Med 1973; 288 (8): 395–8.
13. Goldman MD, Saadeh C, Ross D. Clinical applications of forced oscillation to assess peripheral airway function. Respir Physiol Neurobiol 2005; 148 (1–2): 179–94.
14. Grimby G, Takishima T, Graham W et al. Frequency dependence of flow resistance in patients with obstructive lung disease. J Clin Invest 1968; 47 (6): 1455–65.
15. Evans TM, Rundell KW, Beck KC et al. Airway narrowing measured by spirometry and impulse oscillometry following room temperature and cold temperature exercise. Chest 2005; 128 (4): 2412–9.
16. US National Institutes of Health. The effect of high dose n-acetylcysteine on airtrapping and airway resistance of chronic obstructive pulmonary disease – a double-blinded, randomized, placebo-controlled trial. NCT01136239. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2010, http://www.clinicaltrials.gov/ct2/show/NCT01136239. Updated June 2, 2010.
17. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.org/uploads/users/fi les/GOLD_Report_2011_Feb21.pdf. Accessed December 7, 2012.
18. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152 (3): 1107–36.
19. Ip MS, Ko FW, Lau AC et al; Hong Kong Thoracic Society; American College of Chest Physicians (Hong Kong and Macau Chapter). Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization. Chest 2006; 129 (2): 384–92.
20. Oostveen E, MacLeod D, Lorino H et al; ERS Task Force on Respiratory Impedance Measurements. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003; 22 (6):1026–41.
21. Crim C, Celli B, Edwards LD et al; ECLIPSE investigators. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med 2011; 105 (7): 1069–78.
22. Macklem PT, Mead J. Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol 1967; 22 (3): 395–401.
23. Burgel PR, Bourdin A, Chanez P et al. Update on the roles of distal airways in COPD. Eur Respir Rev 2011; 20 (119): 7–22.
24. Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350 (26): 2645–53.
25. Caramori G, Di Gregorio C, Carlstedt I et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 2004; 45 (5): 477–84.
26. Rabe KF, Hurd S, Anzueto A et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the Downloaded From: http://journal.publications.chestnet.org/by a Zambon Group User on 07/02/2013.
27. Bourdin A, Burgel PR, Chanez P et al. Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. Eur Respir Rev 2009; 18 (114): 198–212.
28. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005; 25 (1): 186–99.
29. King GG, Downie SR, Verbanck S et al. Effects of methacholine on small airway function measured by forced oscilation technique and multiple breath nitrogen washout in normal subjects. Respir Physiol Neurobiol 2005; 148 (1–2): 165–77.
30, Mahut B, Caumont-Prim A, Plantier L et al. Relationships between respiratory and airway resistances and activity-related dyspnea in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2012; 7: 165–71.
31. Brochard L, Pelle G, de Palmas J et al. Density and frequency dependence of resistance in early airway obstruction. Am Rev Respir Dis 1987; 135 (3): 579–84.
32. Faria AC, Costa AA, Lopes AJ et al. Forced oscillation technique in the detection of smoking-induced respiratory alterations: diagnostic accuracy and comparison with spirometry. Clinics (Sao Paulo) 2010; 65 (12): 1295–304.
33. Black PN, Morgan-Day A, McMillan TE et al. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344] [ISRCTN21676344]. BMC Pulm Med 2004; 4: 13.
34. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322 (7297): 1271–4.
35. Benrahmoune M, Therond P, Abedinzadeh Z. The reaction of superoxide radical with N-acetylcysteine. Free Radic Biol Med 2000; 29 (8): 775–82.
36. Gressier B, Cabanis A, Lebegue S et al. Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils: comparison in vitro of some thiol-containing drugs. Methods Find Exp Clin Pharmacol 1994; 16 (1): 9–13.
37. Kharazmi A, Nielsen H, Schiotz PO. N-acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int J Immunopharmacol 1988; 10 (1): 39–46.
38. Stolarek R, Bialasiewicz P, Nowak D. N-acetylcysteine effect on the luminol-dependent chemiluminescence pattern of reactive oxygen species generation by human polymor phonuclear leukocytes. Pulm Pharmacol Ther 2002; 15 (4): 385–92.
39. Borgstrom L, Kagedal B. Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Biopharm Drug Dispos 1990; 11 (2): 131–6.
40, Bridgeman MM, Marsden M, Selby C et al. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49 (7): 670–75.
41. De Benedetto F, Aceto A, Dragani B et al. Long-term oral N-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 2005; 18 (1): 41–7.
42. Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001; 95 (6): 448–56.
43. Demedts M, Behr J, Buhl R et al; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353 (21): 2229–42.
44. Cotgreave IA, Moldeus P. Lung protection by thiol-containing antioxidants. Bull Eur Physiopathol Respir 1987; 23 (4): 275–77.
45. Jeffery PK, Rogers DF, Ayers MM. Effect of oral acetylcysteine on tobacco smoke-induced secretory cell hyperplasia. Eur J Respir Dis Suppl 1985; 139: 117–22.
46. Rubio ML, Sanchez-Cifuentes MV, Ortega M et al. N-acetylcysteine prevents cigarette smoke induced small airways alterations in rats. Eur Respir J 2000; 15 (3): 505–11.
47. Bridgeman MM, Marsden M, MacNee W et al. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 1991; 46 (1): 39–42.
48. Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest 2009; 136 (2): 381–6.
49. Hanaoka M, Droma Y, Chen Y et al. Carbocisteine protects against emphysema induced by cigarette smoke extract inrats. Chest 2011; 139 (5): 1101–8.
50, Rubio ML, Martin-Mosquero MC, Ortega M et al. Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest 2004; 125 (4): 1500–6.
51. Zheng JP, Kang J, Huang SG et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371 (9629): 2013–18.
52. Niederman MS, Rafferty TD, Sasaki CT et al. Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory tract. Am Rev Respir Dis 1983; 127 (1): 85–90.
53. Suer E, Sayrac S, Sarinay E et al. Variation in the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine. J Infect Chemother 2008; 14 (4): 333–6.
54. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21 (5): 795–8.

Hoi Nam Tse, MBChB, FCCP; Luca Raiteri, MD; King Ying Wong, MBBS; Kwok Sang Yee, MBBS; Lai Yun Ng, MBChB; Ka Yan Wa, MBBS; Ching Kong Loo, MBBS; Ming Houng Chan, MBBS